

Establish China partnerships
Create Effective Strategies
to EXPAND YOUR GLOBAL REACH!

Advances in **BIOPHARMACEUTICAL TECHNOLOGY** in CHINA | *New Second Edition!*

A new opportunity exists in working with Chinese companies to establish scientific and business partnerships, and to create effective strategies. However, success in Asia will require changes in partnerships between Western and Asian companies.

*Every company faces the question
“What should our China strategy be?”*

BY THE NUMBERS

- 102 Internationally Recognized Authors
- 21 Peer-Reviewers
- 55 Chapters in 9 Sections
- 7 Case Studies and China Briefs
- 1,139 Pages
- 200+ Tables and Figures
- 300+ References
- Over 2,000 Index Entries

This authoritative, peer-reviewed study is produced in collaboration with the Society for Industrial Microbiology and Biotechnology.

SIMB Society for Industrial Microbiology and Biotechnology

This co-publication with the **Society for Industrial Microbiology and Biotechnology and BioPlan Associates, Inc.**, provides an overview of the biopharmaceutical industry, and the state of technology in China.

Readers will be able to:

1. Assess the state of biopharmaceutical development in China
2. Understand general business practices
3. Analyze business opportunities and identify potential partners

A peer-reviewed, ready reference for all aspects of biopharmaceuticals in China, including an understanding of the China biopharma current situation, and future opportunities.

Readers receive a comprehensive assessment of the state-of-the-industry, trends, and analysis. Information on all types of organizations involved in biopharma in China, whether they are domestic, multinational, or government.

Order Hard Cover
\$6,750

Digital Global License Available

FOR MORE INFORMATION: [Download Table of Contents](#)
or visit <http://bioplanassociates.com/china>

ISBN: 9781934106341





Chapter Preview

SECTION 1: Introduction to Advances in China Biopharmaceuticals

- Introduction: A China Biopharmaceuticals Strategy

SECTION 2: Innovation in China Biopharmaceuticals: Historical and Current Climate

- Biologics Innovation in China: Historical and Current Drivers
- Chinese Innovation in the Biopharmaceutical Industry, 2007 to 2016
- Scientific Strategy in China: Starting with Biosimilar Platforms
- Development of Innovative Therapeutics in China
- Opportunities and Challenges for Drug Innovation in China
- Pathway for Access to China Markets for Innovative Therapeutics
- China on the Biopharmaceutical Fast Track? Challenges to Innovation
- Advances in R&D for mAb Therapeutics Development
- Current Status and Future of China's mAb Therapeutics
- Challenges and Opportunities in Innovative Drug Development in China
- Launching Biologics in China: From Biosimilar to Innovative Molecules.
- Accelerating R&D of Biological Drugs in China
- China's Biopharma Innovation--Creating Opportunities
- Tech Advances in Biopharma

SECTION 3: Biopharmaceuticals and Healthcare Systems and Structure in China

- Overview and Review of the Chinese Biological Pharmaceutical Markets
- Reform of Drug and Medical Device Review and Approval Systems
- China's Regulatory Reform in Healthcare: Achievements and Challenges
- China Food and Drug Administration Reform in China
- Reforms and Trends in China's Healthcare Insurance System
- New Drug Evaluation Systems in China
- Approval Process for Biologics: A US-China Comparison

SECTION 4: Biopharmaceutical Manufacturing in China: Operational and Quality Trends

- Introduction to BioManufacturing in China
- Manufacturing of Biopharmaceuticals in China
- Historical Development of Good Manufacturing Practices in China
- Current Challenges in Biopharma Quality Management in China
- National Standards for Chinese Biological Products
- Advances in China Pharma Manufacturing
- Recombinant Protein Drug Quality Control
- GMP Implementation: The "Made in China 2025" Plan
- Single Use Technology in China's Biomanufacturing
- Biologics Manufacturing Costs in China
- Impact of CFDA Reform on CMC Strategy at IND Stage
- Overview of Biopharmaceutical Contract Manufacturing Organizations in China
- Establishing a Management Pattern for Pharmaceuticals Using the Enterprise Resource Planning System
- Bioprocessing Equipment Strategy in mAb Manufacturing in China

- Tech Transfer in mAb Manufacturing
- Advances in the Biopharmaceutical Manufacturing Industry in China

SECTION 5: Advances in Biological Development in China

- Introduction to Biological Development in China
- Monoclonal Antibody Drug Development in China
- Development of Antibody-Drug Conjugates in China
- Therapeutic Developments for Rare Diseases in China
- CarT-China: Advances in Personalized Medicine
- RNAi in China: Novel Therapeutics in China
- Clinical Trials and Regulatory Oversight of Mesenchymal Stem Cell Therapies in China

SECTION 6: Vaccine Industry in China

- Introduction to China's Vaccine Industry
- Historical Review of China Vaccines: 2007-2016
- Innovative Developments in China's Vaccine Industry
- China's Vaccine Industry: Current Landscape and Key Product Segments
- Current State and Overview of the Chinese Vaccine Market

SECTION 7: Biopharma Contract Services and Clinical Trials in China

- Introduction to China's Services to the Biopharma Industry
- Conducting International Multicenter Clinical Trials in China
- Current and Future Development of CROs in China
- Future of CRO's in China: An Investor's Point of View

SECTION 8: Doing Business in China: Investment and Intellectual Property

- Introduction to Investing in China Pharma and Biopharma Industry
- IP and Biopharma in China
- Trends and Characteristics of Intellectual Property in China's Biopharmaceutical Industry
- Investing in the Biopharmaceutical Industry in China
- An Invitation to Invest in Biomedicine in China
- China's Investment Outbound in the Global Biopharmaceutical Industry
- International Status and Path Analysis of China's Pharmaceutical Products
- China Licensing Deals for Biologics
- Legal Issues: Commercial Bribery in Pharmaceutical Companies in China
- Marketing Authorization Holder Options Under Cost Control
- Industrial Policy and Technology Transfer in China's Biopharma Industry
- Slow Transformation: An Overview of China Pharmaceutical Business
- Intellectual Property Trading in China's Pharmaceutical Industry
- Case Study: Doing Business in China

SECTION 9: Future of China's Biopharma Industry

- Future Prospects for China Biopharma

Appendices

- Directory of Biologics on Market & Clinical Development in China
- Directory: Top 60 Biopharmaceutical Facilities in China

Author Organizations

Amgen Asia Research and Development Center
Anhui Anke Biotechnology (Group) Co., Ltd.
AstraZeneca/MedImmune
AutekBio
BeiGene (Suzhou) Co., Ltd.
Beijing Minhai Biotechnology Co., Ltd.
Beijing University
Beta Pharma Co., Ltd.
Boehringer Ingelheim China
CanSino Biologics Inc.
Celgene Pharma
Cellyan Therapeutics (Wuhan) Co., Ltd.
Changzhou High-Tech Res. Inst. of Nanjing Univ.
China Nat'l Ctr. for Biotechnology Dev. (CNCBD)
China Technology Exchange
Chinese Academy of Sciences

Chinese Pharmacopoeia Commission
Complya Asia Co., Ltd.
CStone Pharmaceuticals
Dacheng LLP
Doer Bio
Fudan University
Genor BioPharma
Guangzhou Nanotides Pharmaceuticals, Co. Ltd.
Hengrui Pharma
Hua Medicine
Huaota Biopharma
ImmuneOnc Biopharmaceuticals (Shanghai) Co., Ltd.
Innova Med Biotechnology Co., Ltd.
Innovent Biologics
Jiangsu TargetPharma Laboratories Inc.
Jiayu (Suzhou) Biomedical Incorporated

Jilin University
L.E.K. Consulting
Macau University of Science and Technology
Nanjing University
Peking University
Perkins Coie, LLP
PersonGen
Pharmcodia
Pullan Consulting
Qiming Venture Partners
Quacell Biotechnology Company Ltd.
Renmin University
SDIC Fund
Shanghai Institutes for Biological Sciences
Shenzhen Polytechnic University
Shenzhen Research Institute of Nanjing University

Sichuan University
Sinolink Securities Institute
Suzhou Sirnaomics Pharmaceuticals, Co. Ltd.
Tasly Sants Pharmaceutical
Tianjin International Joint Academy of Biomedicine
Tot Biopharm Co., Ltd.
VenturePharma
Walter Biotech Consultancy
Wuhan YZY Biopharma Co., Ltd.
WuXi Biologics
Xiamen Wantai Canghai
XingYe Securities
Yusen Capital
Zai Lab.
Zensun (Shanghai) Sci & Tech Co., Ltd.
Zhejiang Hisun Pharmaceutical Co., Ltd.

[Download the Table of Contents](#)

or visit <http://bioplanassociates.com/china>

